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Abstract In order to evaluate the correlation of B7-H4 and
B7-H1 with renal cell carcinoma (RCC), we analyzed B7-H1
and B7-H4 expressions and their clinical significance by im-
munohistochemical method. Our result indicated that B7-H4-
positive staining was detected in 58.13 % of RCC tissues (25
tissues tumors), and there were 18 tissues of patients without
detectable B7-H4. Furthermore, 21 cases (48.83 %) were B7-
H1-positive. Positive tumor expressions of B7-H4 and B7-H1
were markedly related to advanced TNM stage (P=0.001;
P=0.014), high grade (P=0.001; P=002), and larger tumor
size (P=0.002; P=024) in RCC tissues than patients with B7-
H4-negative and B7-H1-negative in RCC tissues. The patients
with B7-H1 and B7-H4-positive expressions were found to be
markedly correlated with the overall survival of the patients
(P<0.05) and tended to have an increased risk of death when
compared with negative expression groups. Univariate
analysis showed that B7-H4 and B7-H1 expressions, TNM
stage, high grade, and tumor size were significantly related
to the prognosis of RCC. Furthermore, multivariate analysis
showed that B7-H4 and B7-H1 expressions decreased overall
survival. The adjusted HR for B7-H1 was 2.83 (95 % CI
1.210–2.971; P = 0.031) and also was 2.918 (95 % CI
1.243–3.102; P=0.006) for B7-H4 that showed these markers
were independent prognostic factors in RCC patients. The
expressions of B7-H1 and B7-H4 in RCC patients indicate
that these markers may be as a predictor of tumor develop-
ment and death risk. Further investigations can be helpful to
confirm B7-H1 and B7-H4 roles as an independent predictor
of clinical RCC outcome.
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Introduction
Renal cell carcinoma (RCC) is the eighth most common can-
cer with the highest mortality rate, over 40% [1, 2]. It has been
shown that many kinds of biomarker alterations and subse-
quent downstream pathways are involved in the development
and progression of tumor. Understanding more about molec-
ular mechanisms is very important to identify biomarkers and
therapeutic targets, especially in the era of targeted therapies
[3, 4]. Despite different prognostic biomarkers for the disease,
the behavior of RCC remains difficult to predict. B7-H1 (PD-
L1), member of the B7 ligand family, is a co-stimulatory
molecule that negatively regulates antitumor cell-mediated
immunity [5, 6], and the aberrant expression of B7-H1 has
been previously reported in many kinds of malignancies
including RCC [7–12].
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Moreover, the overexpression of B7-H1 was reported in
carcinomas of the lung, ovary, breast, colon and renal cells,
and also in melanoma and glioblastoma, and has been ob-
served to impair antitumor T cell immunity [6, 11–14]. B7-
H1 has been reported to have a stimulator function in vivo
tumor regression in different models of murine cancer [15,
16]. B7-H4 is known as a member of the B7 ligand family
that is a negative regulator of T cell cell-mediated immunity
[17]. It has been previously indicated that B7-H4 protein li-
gand expression was increased in the lung, breast, and ovarian
cancer [17–19]. A Previous study has reported the cytoplas-
mic and membranous staining of B7-H4 in invasive carcino-
mas in different kinds of ovarian tumors [20]. It has been
reported that the expression levels of both B7-H4 and B7-
H1 are associated with higher risk of death in RCC patients
[21].
Therefore, the aim of this investigation was to assess the
clinical significance of B7-H1 and B7-H4 in renal cell
carcinoma.
Materials and methods
In this study, the medical records of 43 RCC tissues were
collected from patients who underwent radical or partial ne-
phrectomy at Tehran and Shiraz hospitals between 2008 and
2013 (Fig. 1). Furthermore, adjacent normal tissue specimens
were evaluated. The pathologic characteristics studied includ-
ed tumor size, distant metastases at nephrectomy (M), the
2002 TNM stage groupings, and nuclear grade. Moreover,
the clinical factors studied included age and sex. The clinical
features were summarized in Table 1. The overall survival of
patients was defined as the time elapsed from surgery to death.
Immunohistochemistry
Immunohistochemistry was done using 4-μm formalin-fixed
paraffin-embedded tissue sections and then dewaxed in xy-
lene, rinsed in graded ethanol, and followed by rehydration
by using distilled water. Antigen retrieval was performed
using heating tissue slides in ethylenediaminetetra acetic acid
(EDTA) 1 mmol/L (pH 8) to 121 °C using a Digital Decloing
Chamber (Biocare Medical, Concord, CA, USA), after
cooling to 90 °C (incubation was done for 5 min). Then, the
sections were treated with a peroxidase blocking solution to
block endogenous peroxidase activity. The sections’ incuba-
tion was done in 1:100 dilution of mouse anti-B7-H1 mono-
clonal antibody (clone 5H1) and mouse antihuman B7-H4
monoclonal antibody (clone hH4.1), respectively. The slides
were incubated with a horseradish peroxidase-conjugated an-
ti-biotin antibody. DAB was used as the chromogen, and
slides were counterstained with hematoxylin. The tumor cell
percentages (positive B7-H4 and B7-H1 staining) were
quantified in 5 % increments. Tumors with <5 % of tumor
staining were assigned into negative expression.
Statistical analysis
All variables were analyzed using the SPSS 19.0 (SPSS Inc.,
Chicago, IL, USA). The correlation of expression with clini-
copathological features in patients was studied using X2. Sur-
vival curves were plotted using the Kaplan-Meier method and
analyzed by the log-rank test. Univariate and multivariate Cox
regression analyses were applied to assess the survival. Statis-
tical analysis was considered to be statistically significant
P<0.05.
Results
Immunohistochemical staining results
B7-H4 and B7-H1 staining displayed a heterogeneous stain-
ing pattern with a median level of staining of 20 and 25 %
(range 10–100 %; 5–90 %). The patients were assigned into
positive or negative groups based on whether B7-H1 and B7-
H4 were present or absent. Our result indicated that B7-H4-
positive staining was detected in 58.13 % of RCC tissues (25
tissues tumors), and there were 18 tissues of patients without
detectable B7-H4. Furthermore, 21 cases (48.83 %) were B7-
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Fig. 1 Immunohistochemical staining of B7-H1 and B7-H4 and their
co r r e l a t i on wi th su rv iva l i n RCC. a–d Represen t a t i ve
immunohistochemical staining of the positive and negative expressions
of RCC
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H1-positive. Only 6 tissues of 20 adjacent tissues showed
positive B7-H4 expression. There was no or very weak B7-
H1 staining in the adjacent normal tissue specimens. The pos-
itive tumor expression of B7-H4 and B7-H1 were significant-
ly correlated with advanced TNM stage (P = 0.001;
P=0.014), high grade (P=0.001; P=002), and larger tumor
size (P=0.002; P=024) in RCC tissues compared with pa-
tients with B7-H4-negative and B7-H1-negative in RCC tis-
sues (Table 1).
Combination of B7-H1 and B7-H4-positive staining
Our result indicated that tumors with B7-H1-positive staining
were more likely to be B7-H4-positive in comparison with
tumors tissues that showed to be B7-H1-negative
(P = 0.006). B7-H1/B7-H4-positive staining tissues were
markedly more likely to have adverse clinical and pathologi-
cal characteristics.
Positive B7-H1 and B7-H4 expressions are correlated
with poor overall survival
Kaplan-Meier survival and log-rank analysis were done to
evaluate the relationship of B7-H4 and B7-H1 expressions
with the survival of patients. The patients with B7-H1 and
B7-H4-positive expressions were found to be markedly cor-
related with the overall survival of the patients (P<0.05) and
tended to have an increased risk of death when compared with
negative expression groups. Univariate analysis indicated that
B7-H4 and B7-H1 expressions, TNM stage, high grade, and
tumor size were significantly correlated with the prognosis of
RCC (Table 2). Furthermore, multivariate analysis showed
that B7-H4 and B7-H1 expressions decreased overall survival.
The adjusted HR for B7-H1 was 2.83 (95 % CI 1.210–2.971;
P = 0.031) and also was 2.918 (95 % CI 1.243–3.102;
P=0.006) for B7-H4, that showed these markers were inde-
pendent prognostic factors in RCC patients (Table 2).
Discussion
The aberrant expression of B7-H1 has been previously ob-
served in various malignancies including RCC [7–12]. Fur-
thermore, the overexpression of B7-H1 has been indicated in
carcinomas of the lung, ovary, breast, colon, renal cells, mel-
anoma, and glioblastoma, and has been observed to impair
antitumor T cell immunity [6, 11–14]. B7-H1 has been found
to have stimulator function in vivo tumor regression in
Table 1 Clinical and pathologic
features by tumor B7-H4 and B7-
H1 expressions
Parameter Number B7-H4 P value of
B7-H4
B7-H1 P value
of B7-H1
43 Positive
(n= 25)
Negative
(n = 18)
Positive
(n = 21)
Negative
(n = 22)
Age 0.591 0.325
< 55 20 12 8 7 13
≥ 55 23 13 10 14 9
Sex 0.542 0.641
Male 21 10 11 8 13
Female 22 15 7 13 9
Primary tumor size,
centimeter
0.002 0.024
<5 18 8 10 7 11
5 to <7 14 8 6 6 8
≥7 11 9 2 8 3
Distant metastases at
nephrectomy
0.129 0.251
pM0 28 15 13 16 12
Pm1 15 10 5 5 10
TNM stage groupings 0.001 0.014
I/II 25 11 14 10 15
III/IV 18 14 4 11 7
Nuclear grade
1 14 6 8 0.001 3 11 0.002
2 8 5 3 4 4
3 10 6 4 7 3
4 11 8 3 7 4
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different models of murine cancer [15, 16]. The expression of
tumor-associated B7-H1 is related to poor prognosis and high
grade of malignancy. The blockade of tumor-related B7-H1
has been reported to elevate tumor regression in vivo in dif-
ferent kinds of murine tumor transplants [6, 14–16]. In the
present study, we found that 21 cases (48.83 %) were B7-
H1-positive. There was no or very weak B7-H1 staining in
the adjacent normal tissue specimens. The positive tumor ex-
pression of B7-H1 was significantly linked to advanced TNM
stage, high grade, and larger tumor size in RCC tissues com-
pared with patients with B7-H1-negative in RCC tissues.
The patients with B7-H1-positive expression tended to
have an increased risk of death when compared with negative
expression groups. Univariate analysis indicated that B7-H1
expressions, TNM stage, high grade, and tumor size were
significantly correlated with the prognosis of RCC. Further-
more, multivariate analysis showed that B7-H1 expressions
decreased overall survival, and this marker was an indepen-
dent prognostic factor in RCC patients.
In this study, we provided evidence that the positive ex-
pression of B7-H1 is associated with adverse clinical and
pathologic characteristics in renal cell carcinoma. This finding
is in agreement with a previous finding that indicated TNM
stage and nuclear grade are clinical predictors of outcome in
patients suffering from RCC [22, 23]. The aberrant expression
of B7-H1 has been reported in human RCC and low expres-
sion of B7-H1 in overall survival [12, 24]. Survival rate by
mentioned predictive indices among patients with RCC, but
tends to be variable, indicating the heterogeneous behavior of
RCC [24]. Hence, our result indicated that tumor B7-H1 ex-
pression is independently associated with the risk of cancer
progression. The expression of tumor-associated B7-H1 is
related to poor prognosis and high grade of malignancy
[14–16]. Moreover, it has been shown that B7-H1 expression
could be a prognostic factor independent in many kinds of
malignancy such as colorectal cancer and RCC [12, 23, 25].
It has been reported that the expression levels of B7-H1 are
associated with greater risk of death in patients with RCC
tumors [21].
Moreover, our result indicated that B7-H4-positive staining
was detected in 58.13 % of RCC tissues. Only 6 tissues of 20
adjacent normal tissues showed positive B7-H4 expression.
The positive tumor expression of B7-H4 was significantly
correlated with advanced TNM stage, high grade, and larger
tumor size in RCC tissues compared with patients with B7-
H4-negative in RCC tissues.
In the present study, the patients with B7-H4-positive ex-
pression was found to be markedly correlated with the overall
survival of the patients and tended to have an increased risk of
death when compared with negative expression groups. Uni-
variate analysis indicated that B7-H4 expression, TNM stage,
high grade, and tumor size were significantly correlated with
the prognosis of RCC. Furthermore, multivariate analysis
showed that high expression of B7-H4 is related to the de-
crease of overall survival. The adjusted HR for B7-H4 showed
that this marker was an independent prognostic factor in RCC
patients. B7-H4 has been shown to be overexpressed in vari-
ous kinds of tumors, including, non-small cell lung breast,
ovarian cancers, and lobular breast cancer, etc., compared to
normal tissues [19, 26, 27]. Previous study has reported that
the cytoplasmic and membranous patterns of B7-H4 staining
were detected only in invasive carcinomas in various forms of
ovarian tumors [20]. Thus, the overexpression of B7-H4 may
make it an effective target for facilitating antitumoral immu-
notherapeutic responses in malignant tissues. Previous studies
indicated that B7-H4 may negatively regulate T cell responses
[17]. Furthermore, it has been suggested that B7-H4 has a
direct role in preventing apoptosis in tumor cell. The overex-
pression of B7-H4 can elevate tumor development in SCID in
ovarian cancer cell lines. It was shown that the knockdown of
B7-H4 mRNA and expression of protein can elevate intracel-
lular caspase activity in the SKBR3 cell line of breast cancer
Table 2 Cox regression analysis
of prognostic factors for overall
survival in RCC patients
Univariate Multivariate
HR 95 % CI P value HR 95 % CI P Value*
B7-H4 expression 2.832 (1.134–3.723) 0.003 2.918 (1.243–3.102) 0.006
Age 0.732 (0.534–1.521) 0.513 0.910 (0.623–1.742) 0.647
Sex 1.03 (0.892–2.071) 0.315 1.142 (0.723–1.891) 0.352
Primary tumor size, centimeter 2.791 (1.035–3.631) 0.006 2.723 (1.127–3.04) 0.002
TNM stage 2.90 (1.09–3.537) 0.011 2.562 (1.190–2.971) 0.02
Distant metastases at
nephrectomy
1.573 (0.871–2.21) 0.231 1.152 (0.712–1.623) 0.312
Nuclear grade 2.811 (1.321–3.629) 0.007 2.623 (1.318–3.024) 0.01
B7-H1 expression 2.781 (1.125–3.621) 0.008 2.83 (1.210–2.971) 0.031
95 % CI indicates 95 % confidence interval
*P ≤ 0.05
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and promote tumor cell apoptosis [19]. It has been reported
that B7-H4 expression was linked to adverse clinical and path-
ologic characteristics in RCC tissues. It was indicated that the
expression level of B7-H4 is linked to greater risk of death in
patients with RCC tumors [21]. The correlation between the
tumor expression of B7-H4 and outcome observed in our
study is consistent with those reported by the abovementioned
study. We found that B7-H4 expression is correlated with an
increased risk of death and disease progression in RCC pa-
tients. Current evidence indicates that B7-H4 functions as an-
titumoral immunity inhibitor or extends tumor cell survival.
The correlation of B7-H4 expression with the progression and
survival of RCC patients may implicate for future therapy. The
expressions of B7-H1 and B7-H4 in RCC patients indicate
that these markers may be as predictor of tumor development
and death risk.
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